Caroline Pétorin

1.6k total citations
18 papers, 217 citations indexed

About

Caroline Pétorin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Caroline Pétorin has authored 18 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Caroline Pétorin's work include Pancreatic and Hepatic Oncology Research (6 papers), Neuroendocrine Tumor Research Advances (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Caroline Pétorin is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), Neuroendocrine Tumor Research Advances (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Caroline Pétorin collaborates with scholars based in France, United Kingdom and Belgium. Caroline Pétorin's co-authors include Bruno Pereira, Côme Lepage, Denis Pezet, Jean–Marc Phelip, Karine Le Malicot, Thomas Aparicio, Bertrand Le Roy, Laëtitia Dahan, Frédéric Costes and Marie Selvy and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Caroline Pétorin

14 papers receiving 213 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline Pétorin France	8	152	56	52	50	41	18	217
Sandrine Oziel-Taïeb France	7	97 0.6×	42 0.8×	44 0.8×	27 0.5×	23 0.6×	19	247
G Pastorino Italy	9	162 1.1×	43 0.8×	28 0.5×	57 1.1×	47 1.1×	21	267
Tsuneo Shimokawa Japan	9	155 1.0×	35 0.6×	35 0.7×	161 3.2×	25 0.6×	56	294
Giuseppina Arcangeli Italy	7	227 1.5×	69 1.2×	24 0.5×	101 2.0×	27 0.7×	11	336
Els Monsaert Belgium	6	174 1.1×	60 1.1×	44 0.8×	61 1.2×	87 2.1×	17	228
J. Selleslags Belgium	6	194 1.3×	34 0.6×	34 0.7×	64 1.3×	72 1.8×	7	243
Tiziana Panigalli Italy	9	187 1.2×	102 1.8×	74 1.4×	243 4.9×	39 1.0×	13	419
Rumi Itoyama Japan	12	176 1.2×	129 2.3×	57 1.1×	72 1.4×	57 1.4×	40	319
Maria Maddalena Laterza Italy	10	192 1.3×	81 1.4×	58 1.1×	143 2.9×	79 1.9×	35	342
Alessandra Galligioni Italy	10	89 0.6×	99 1.8×	146 2.8×	68 1.4×	32 0.8×	18	355

Countries citing papers authored by Caroline Pétorin

Since Specialization

Citations

This map shows the geographic impact of Caroline Pétorin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Pétorin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Pétorin more than expected).

Fields of papers citing papers by Caroline Pétorin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Pétorin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Pétorin. The network helps show where Caroline Pétorin may publish in the future.

Co-authorship network of co-authors of Caroline Pétorin

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Pétorin. A scholar is included among the top collaborators of Caroline Pétorin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Pétorin. Caroline Pétorin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Taı̈eb, Julien, Simon Pernot, Caroline Pétorin, et al.. (2025). 5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61).. Journal of Clinical Oncology. 43(16_suppl). 4184–4184.

Martin, E., Karine Le Malicot, Catherine Guérin‐Charbonnel, et al.. (2024). How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology. Current Oncology. 31(6). 3513–3528.

Walter, Thomas, Thierry Lecomte, Julien Hadoux, et al.. (2023). LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network. Annals of Oncology. 34. S1292–S1293. 5 indexed citations

Balayssac, David, Bruno Pereira, Carine Chaleteix, et al.. (2023). Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study. European Journal of Cancer Care. 2023. 1–9.

Péréon, Yann, Maxime Leroy, Olivier Lépine, et al.. (2023). PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy. Trials. 24(1). 50–50. 4 indexed citations

Ginzac, Angeline, Émilie Thivat, Caroline Pétorin, et al.. (2023). A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?. Cancer Chemotherapy and Pharmacology. 93(3). 225–236. 3 indexed citations

Lepage, Côme, Astrid Lièvre, Laëtitia Dahan, et al.. (2022). Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. European Journal of Cancer. 175. 31–40. 13 indexed citations

Dahan, Laëtitia, Nicolas Williet, Karine Le Malicot, et al.. (2021). Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Journal of Clinical Oncology. 39(29). 3242–3250. 45 indexed citations

Lepage, Côme, Jean–Marc Phelip, Astrid Lièvre, et al.. (2020). 1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial. Annals of Oncology. 31. S774–S774. 5 indexed citations

10.

Taı̈eb, Julien, Jean–Marc Phelip, Yves Rinaldi, et al.. (2018). Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer. Annals of Oncology. 29. viii244–viii244. 1 indexed citations

11.

Dahan, Laëtitia, Jean–Marc Phelip, Karine Le Malicot, et al.. (2018). FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).. Journal of Clinical Oncology. 36(15_suppl). 4000–4000. 37 indexed citations

12.

Montanier, Nathanaëlle, et al.. (2017). The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy. Medicine. 96(6). e6062–e6062. 9 indexed citations

13.

Roy, Bertrand Le, Bruno Pereira, Corinne Bouteloup, et al.. (2016). Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial—the PREHAB study. BMJ Open. 6(12). e012876–e012876. 51 indexed citations

14.

Roy, Bertrand Le, Bruno Pereira, Pierre Sauvanet, et al.. (2016). Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. PLoS ONE. 11(2). e0148739–e0148739. 12 indexed citations

15.

Balayssac, David, Jérémy Ferrier, Bruno Pereira, et al.. (2015). Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet—NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open. 5(4). e007479–e007479. 19 indexed citations

16.

Authier, Nicolas, Caroline Pétorin, Denis Pezet, & Alain Eschalier. (2006). Neurotoxicité périphérique des traitements oncologiques: aspects précliniques et cliniques. ONCOLOGIE. 8(10). 895–900.

17.

Gaboury, Louis, et al.. (2001). The Value of Clonality in the Diagnosis and Follow-up of Patients With Cutaneous T-cell Infiltrates. Diagnostic Molecular Pathology. 10(2). 78–88. 12 indexed citations

18.

Eghbali, Houchingue, Caroline Pétorin, I. de Mascarel, et al.. (1994). [Lymphoid depletion type 4 Hodgkin disease. Anatomoclinical review of 35 cases].. PubMed. 81(10). 866–70. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact